Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-1017
      • ALG.APV-527
      • NEO-X-PRIME
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-FAB™
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • Preferential Rights Issue Q4 2021
    • Preferential rights issue Q1 2021
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Subscribe
  • Contact
  • SV
Start > Research and development > Scientific publications
  • Scientific publications
  • Immunotherapy of cancer
  • Pipeline
  • Technology platform
  • Scientific advisors
  • ATOR-1017, a second generation 4-1BB antibody with potential to enhance efficacy of PD-1 therapies
    Karin Enell Smith, Anneli Nilsson, and Peter Ellmark, Poster SITC, November 12, 2021
  • Neo-X-Prime™ bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigens and induce a superior anti-tumor response
    Karin Hägerbrand, Laura Varas, Mattias Levin, Laura von Schantz, Anna Säll, Adnan Deronic, Anette Sundstedt, Lill Ljung, Karin Barchan, Doreen Werchau, Anna Rosén, Maria Johansson, Barnabas Nyesiga, Eva Lindqvist, Mia Thagesson and Peter Ellmark, Poster SITC, November 12, 2021
  • OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
    Yago Pico de Coaña, Karin Enell Smith, Anette Fält, Maria Flärdh, Peter Ellmark, Philippe Cassier, Jean-Luc van Laethem and Malin Carlsson, Poster SITC, November 12, 2021
  • ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors
    Michelle H. Nelson, Anette Sundstedt, Yago Pico de Coaña, Ashly Lucas, Anneli Nilsson, Lill Ljung, Allison Chunyk, Lena Schultz, Catherine McMahan, Jane Gross, Sara Frizell, Hilario Ramos and Peter Ellmark, Poster SITC, November 12, 2021
  • Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
    Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén and Peter Ellmark, Expert Opinion on Biological Therapy, June 17, 2021
  • A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
    Gustav J. Ullenhag, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Peter Ellmark, Karin Enell Smith, Tina Hjorth, Tova Landström, Poster ASCO, June 7, 2021
  • Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy
    Adnan Deronic, Mia Thagesson, Anneli Nilsson, Peter Ellmark, Anette Fält, Charlotte Russell and Karin Enell Smith*, Poster AACR, April 10, 2021
  • A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of monospecific antibodies
    Karin Hägerbrand, Mattias Levin, Laura von Schantz, Adnan Deronic, Laura Varas, Anna Säll, Karin Barchan, Doreen Werchau, Lill Ljung, Mia Thagesson, Anna Rosén, Christina Sakellariou, Malin Lindstedt and Peter Ellmark, Poster SITC November 9, 2020
  • Potent Tumor-Directed T-cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    Michelle Nelson, Robert Miller, Anneli Nilsson, Lill Ljung, Allison Chunyk, Catherine McMahan, David Bienvenue, Maria Askmyr, Gabriela Hernandez-Hoyos and Sara Fritzell, Poster SITC November 9, 2020
  • Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies
    Jeffrey Yachnin, Gustav J. Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten and Charlotte Astrid Russell, Poster SITC November 9, 2020
  • Mitazalimab – a CD40 agonist to unleash CD40 in immuno-oncology
    Peter Ellmark, PhD, Ass. Prof, VP Discovery Alligator Bioscience, World Immunotherapy Congress, November 5, 2020
  • A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody
    Jeffrey Yachnin , Gustav J. Ullenhag , Ana Carneiro , Dorte Nielsen , Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten, Charlotte Astrid Russell, Poster ASCO May 20, 2020
  • A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody
    Jeffrey Yachnin, Gustav J. Ullenhag, Ana Carneiro, Dorte L. Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Erika Bågeman, Camilla S. Wennersten, Charlotte Astrid Russell, AACR Virtual Annual Meeting, access through link, https://www.youtube.com/channel/UCblfdPkN76f_NTD0qBtJlBg/videos
  • ATOR-1017, a 4-1BB Antibody Developed for Tumor-Directed Immunotherapy of Cancer
    D Werchau, A Rosén, M Eriksson, S Järnum, C Furebring and K Enell Smith, Poster SITC November 9, 2019
  • Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    M Nelson, R Miller, R Bader, D Werchau, A Nilsson, L Ljung, A Deronic, A Chunyk, L Schultz, C McMahan, D Bienvenue, A Dahlman, S Fritzell, M Askmyr, G Hernandez-Hoyos, Poster SITC November 9, 2019
  • 4224, a tumor exosome-transforming antibody targeting CD40 and EpCAM, induces superior anti-tumor effects compared to monospecific CD40 antibody
    Adnan Deronic, Laura von Schantz, Mia Thagesson, Kristine Smedenfors, Christina Sakellariou, Lill Ljung, Fredrika Carlsson, Doreen Werchau, Malin Lindstedt, Peter Ellmark, Karin Hägerbrand, CICON, 26 September 2019
  • A first-in-human, multicenter, open-label, phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015
    Jeffrey Yachnin, Gustav J Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Anna Dahlman, Erika Bågeman, Camilla Wennersten , Charlotte Astrid Russell., Poster ASCO, June 1, 2019,
  • RUBY TM – A novel recombinant universal bispecific antibody format for generation of bsAb with outstanding stability, manufacturability and shorter development timelines
    A Säll, M Levin, B Nyesiga, M Mårtensson, S Fritzell, K Hägerbrand, C Furebring, L von Schantz, Poster PEGS 11 April 2019
  • ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells
    S Fritzell, M Levin, A Dahlman, I Åberg, M Johansson, M Winnerstam, K Enell Smith, P Ellmark, C Furebring, P Norlén, A Månsson Kvarnhammar , AACR Annual Meeting April 2, 2019
  • Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
    A Dahlman, M Nelson, J Bannink, Starrla Johnson, D Werchau, A Nilsson, L Ljung, G Blahnik-Fagan, R Bader, P Ellmark, M Askmyr, G Hernandez-Hoyos, C McMahan, S Fritzell, AACR Annual Meeting April 1, 2019
  • The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Dahlman, Anna Rosén, Maria Johansson, Ida Åberg, Per Norlén, Christina Furebring and Peter Ellmark, SITC November 9, 2018
  • ATOR-1017, a tumor directed Fcγ-receptor cross-linking dependent ATOR-1017, a tumor directed Fcγ-receptor cross-linking dependent
    Karin Enell Smith, Anna Rosén, Anna Dahlman, Karin Barchan, Ida Åberg, Doreen Werchau, Mia Thagesson, Niina Veitonmäki, Christina Furebring and Peter Ellmark, SITC November 9, 2018
  • Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    Michelle Nelson, Gabriele Blahnik-Fagan, Robert Bader, Doreen Werchau, Anneli Nilsson, Lill Ljung, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Catherine McMahan, David Bienvenue, Maria Askmyr, Anna Dahlman, Peter Ellmark, Gabriela Hernandez-Hoyos and Sara Fritzell , SITC November 9, 2018
  • ATOR-1017; a 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy
    Eva Dahlén, Anna Rosén, Adnan Deronic, Karin Barchan, Anna Dahlman, Peter Ellmark, Tina Furebring and Karin Enell Smith, 4th CRI-CIMT-EATI-AACR International Cancer lmmunotherapy Conference September 30, 2018
  • The agonistic CD40 antibody improves T cell responses and delays growth of a syngeneic tumor in an ovalbumin vaccination model
    Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Niina Veitonmäki, Per Norlén, Christina Furebring and Peter Ellmark, World Preclinical Congress June 2018
  • CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Maria Johansson, Per Norlén, Christina Furebring and Peter Ellmark, Poster CIMT May 16, 2018
  • Tumor Antigen-dependent T Cell Activation And Tumor Localization Induced By A Novel 4-1BB X 5T4 ADAPTIR™ Bispecific Antibody
    Sara Fritzell, Doreen Werchau, Maria Askmyr, Niina Veitonmäki, Anneli Nilsson, Adnan Deronic, Mia Thagesson, Anna Säll, Laura von Schantz, Robert Bader, Gabriele Blahnik-Fagan, Michelle Nelson, David Bienvenue, Gabriela Hernandez-Hoyos, Peter Ellmark , Poster CIMT May 16, 2018
  • Activation of the CD137 Pathway in T cells by a CD137 x 5T4 bispecific ADAPTIR™ Molecule Requires Co-engagement of CD137 and 5T4
    Gabriele Blahnik-Fagan, Robert Bader, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Cathy McMahan, David Bienvenue, Laura von Schantz, Eva Lindqvist, Doreen Werchau, Anneli Nilsson, Maria Askmyr, Niina Veitonmäki, Sara Fritzell, Peter Ellmark, Michelle Nelson1, and Gabriela Hernandez-Hoyos, Poster AAI May 5, 2018
  • Design and Generation of Bispecific Antibodies for Immuno-Oncology
    von Schantz L, Säll A, Carlsson F, Thorulffsson M, Petersson J, Tsiobanelis K, Nyesiga B, Jansson K, Rosén A, Hägerbrand K, Dahlman A, Månsson-Kvarnhammar A, Veitonmäki N and Furebring C., Poster PEGS May 2, 2018
  • Screening, Optimization and Characterization of a Novel 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
    von Schantz L, Misher L, Mitchell D, Gruswitz F, Woodruff B, Daugherty M, Aguilar M, Huntington K, Bader R, Blahnik-Fagan G, Säll A, Werchau D, Thagesson M, Nilsson A, Deronic A, Askmyr M, Veitonmäki N, Fritzell S, Ellmark P, Hernandez-Hoyos G and Bienvenue D., Poster PEGS May 2, 2018
  • CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Veitonmäki N, Månsson Kvarnhammar A, Fritzell S, Enell Smith K, Thagesson M, Werchau D, Hägerbrand K, Rosén A, Johansson M, Norlén P, Furebring C, Ellmark P, Poster AACR April 17, 2018
  • Bispecific antibodies in cancer immunotherapy
    Eva Dahlén, Niina Veitonmäki and Per Norlén , Therapeutic advances in vaccines and immunotherapy, 2018, Vol. 6(1) 3–17,

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

Kakor
Vi bjuder på kakor! Om du tycker det är ok, klickar du bara på "Acceptera alla". Du kan såklart välja vilken typ av kakor du vill ha genom att klicka på "Inställningar". Läs vår privacy policy
Inställningar Neka alla Acceptera alla
Kakor
Välj vilken typ av kakor du vill acceptera. Ditt val kommer att sparas i ett år. Läs vår privacy policy
  • Nödvändiga
    Dessa kakor går inte att välja bort. De behövs för att hemsidan över huvud taget ska fungera.
  • Statistik
    För att vi ska kunna förbättra hemsidans funktionalitet och uppbyggnad, baserat på hur hemsidan används.
  • Upplevelse
    För att vår hemsida ska prestera så bra som möjligt under ditt besök. Om du nekar de här kakorna kommer viss funktionalitet att försvinna från hemsidan.
  • Marknadsföring
    Genom att dela med dig av dina intressen och ditt beteende när du surfar ökar du chansen att få se personligt anpassat innehåll och erbjudanden.
Spara Neka alla Acceptera alla